The Experts below are selected from a list of 270 Experts worldwide ranked by ideXlab platform

Motohiko Kato - One of the best experts on this subject based on the ideXlab platform.

  • percutaneous endoscopic gastrostomy under Steady Pressure automatically controlled endoscopy first clinical series
    World Journal of Gastrointestinal Endoscopy, 2016
    Co-Authors: Hiroyuki Imaeda, Kiyokazu Nakajima, Naoki Hosoe, Masanori Nakahara, Shinichiro Zushi, Motohiko Kato, Kazuhiro Kashiwagi, Yasushi Matsumoto, Kayoko Kimura, Rieko Nakamura
    Abstract:

    Percutaneous endoscopic gastrostomy under Steady Pressure automatically controlled endoscopy: First clinical series

  • gastric endoscopic submucosal dissection under Steady Pressure automatically controlled endoscopy space a multicenter randomized preclinical trial
    Surgical Endoscopy and Other Interventional Techniques, 2015
    Co-Authors: Takuya Yamada, Tsuyoshi Takahashi, Motohiko Kato, M Hirota, Shusaku Tsutsui, Kazuhiro Yasuda, Kazuki Sumiyama, Masahiko Tsujii, Tetsuo Takehara, Masaki Mori
    Abstract:

    Background Steady Pressure automatically controlled endoscopy (SPACE) is a new modality that eliminates on-demand insufflation but enables automatic insufflation in the gastrointestinal tract. Though its use in porcine esophageal ESD was reported to be promising, its applicability and potential effectiveness to gastric procedures have not been evaluated.

  • esophageal submucosal dissection under Steady Pressure automatically controlled endoscopy space a clinical feasibility study
    Endoscopy, 2014
    Co-Authors: Motohiko Kato, Makoto Yamasaki, Masaki Mori, Yuichiro Doki, Kiyokazu Nakajima, Takuya Yamada, M Hirota, Yasuaki Miyazaki, Tsutomu Nishida, Masahiko Tsujii
    Abstract:

    Background and study aims: Steady Pressure automatically controlled endoscopy (SPACE) is a new insufflation system that provides constant carbon dioxide (CO2) insufflation Pressure during prolonged procedures. The system consists of an overtube, a surgical insufflator, and a newly developed leak-proof valve. The aims of this study were to validate the feasibility and safety of SPACE for esophageal endoscopic submucosal dissection (ESD). Patients and methods: This was a clinical phase I trial, involving 10 patients who underwent esophageal ESD. The primary end point was the rate of adverse events within 30 days (grade 0 to 4). Secondary end points were changes in partial Pressure of carbon dioxide (PaCO2) and vital signs during ESD, completion rate of ESD, and degree of abdominal distension by patient assessment and radiographic grading. Results: All adverse events were Grade 2 or less. Mild PaCO2 elevation after ESD was noted; however, no associated symptoms were reported. The procedure was completed under SPACE alone in 8 of 10 patients. Minimal post-procedural bowel distension was observed. Conclusions: In this small pilot study, SPACE was feasible and appeared to be safe. Further study with larger case numbers is required to demonstrate efficacy and safety. Clinical trial registration: UMIN000005434

  • esophageal submucosal dissection under Steady Pressure automatically controlled endoscopy space a randomized preclinical trial
    Endoscopy, 2012
    Co-Authors: Kiyokazu Nakajima, Makoto Yamasaki, Motohiko Kato, Shusaku Tsutsui, Kazuhiro Yasuda, Kazuki Sumiyama, Yasuaki Miyazaki, Jeongho Moon, Tomomi Yamada, Naohisa Yahagi
    Abstract:

    Background and study aims: A new overtube system has been developed for Steady Pressure automatically controlled endoscopy (SPACE) in the gastrointestinal tract. The objectives of this study were to validate the feasibility and safety of SPACE in the esophagus, and to evaluate its potential advantages over conventional (manually insufflating) endoscopy in endoscopic submucosal dissection (ESD). Methods: This was a multicenter preclinical trial using acute porcine models (n = 20). In Experiment 1 (feasibility/safety study), SPACE was attempted in the esophagus with continuous monitoring of cardiopulmonary parameters and intraluminal Pressures in the downstream bowel. Different insufflation Pressures were tested to optimize the insufflation condition. Each session was video-recorded and scored by blinded reviewers. In Experiment 2 (randomized trial), esophageal ESD was attempted using either SPACE or conventional endoscopy, and results were compared. Results: In Experiment 1, SPACE was performed safely without intraluminal Pressure elevation in the downstream bowel. According to video review, SPACE provided more stable, reproducible, and rapid visualization than conventional endoscopy. The insufflation Pressure was optimized at 14 mmHg for esophageal SPACE. In Experiment 2, ESD was completed in all animals. The ESD time was significantly shorter with SPACE compared with conventional endoscopy (1326 vs. 1616 seconds; P  = 0.009). Responses to questionnaires showed that 94 % – 100 % of participants considered SPACE to provide improved exposure and more uniform tissue tension than conventional endoscopy. Other data were comparable. Conclusions: SPACE is feasible, safe, and potentially effective for complicated endoscopic procedures, such as ESD. SPACE improves and standardizes endoscopic exposure and tissue tension. A clinical study is required to further confirm its safety and clinical effectiveness.

Masaki Mori - One of the best experts on this subject based on the ideXlab platform.

  • gastric endoscopic submucosal dissection under Steady Pressure automatically controlled endoscopy space a multicenter randomized preclinical trial
    Surgical Endoscopy and Other Interventional Techniques, 2015
    Co-Authors: Takuya Yamada, Tsuyoshi Takahashi, Motohiko Kato, M Hirota, Shusaku Tsutsui, Kazuhiro Yasuda, Kazuki Sumiyama, Masahiko Tsujii, Tetsuo Takehara, Masaki Mori
    Abstract:

    Background Steady Pressure automatically controlled endoscopy (SPACE) is a new modality that eliminates on-demand insufflation but enables automatic insufflation in the gastrointestinal tract. Though its use in porcine esophageal ESD was reported to be promising, its applicability and potential effectiveness to gastric procedures have not been evaluated.

  • Dynamic article: Steady Pressure CO2 colonoscopy; its feasibility and underlying mechanism.
    Diseases of The Colon & Rectum, 2014
    Co-Authors: Masashi Hirota, Yasuhiro Miyazaki, Tsuyoshi Takahashi, Makoto Yamasaki, Shuji Takiguchi, Masaki Mori, Yuichiro Doki, Kiyokazu Nakajima
    Abstract:

    Steady Pressure automatically controlled endoscopy is a new insufflation concept, achieving a laparoscopy-like Steady environment in the upper GI tract, recently reported in the esophagus. The purpose of this work was to validate the feasibility and safety of Steady Pressure automatically controlled endoscopy in the lower GI tract and to identify major factors that enable it. This was a nonsurvival animal study using canine models. The study was conducted in an academic center. Canine models were used in this study. In experiment 1, Steady Pressure automatically controlled endoscopy was attempted in the cecum with insufflation Pressures of 4, 8, and 12 mm Hg. We assessed performance by video review and continuous intracecal Pressure monitoring. Next, Steady Pressure automatically controlled endoscopy was performed for 20 minutes under optimal Pressure, 8 mm Hg (n = 10). In experiment 2, Steady Pressure automatically controlled endoscopy was attempted in the rectum with or without artificial colonic flexure and with either low (8 mm Hg) or high (16 mm Hg) insufflation Pressure to assess the effects of anatomic flexure and insufflation Pressure on the establishment of Steady Pressure automatically controlled endoscopy (n = 6). We measured multipoint intraluminal Pressure monitoring in the upstream bowel, as well as cardiopulmonary parameters. For experiment 1, Steady Pressure automatically controlled endoscopy in cecum was successful at all of the tested insufflation Pressures; 8 mm Hg provided the optimal result. Steady Pressure automatically controlled endoscopy was safely performed for 20 minutes at 8 mm Hg without any cardiopulmonary parameter changes or intraluminal Pressure elevation in the upstream bowel. For experiment 2, confinement of the Steady Pressure environment to the rectum was achieved only with the assistance of colonic flexure and at 8 mm Hg insufflation Pressure. In other conditions, the insufflated gas extended throughout the entire colon. This study was limited by being an animal study. Steady Pressure automatically controlled endoscopy is feasible and safe in the lower GI tract under the optimized insufflation Pressure and in the presence of anatomical flexure (see Video, Supplemental Digital Content 1, http://links.lww.com/DCR/A150).

  • esophageal submucosal dissection under Steady Pressure automatically controlled endoscopy space a clinical feasibility study
    Endoscopy, 2014
    Co-Authors: Motohiko Kato, Makoto Yamasaki, Masaki Mori, Yuichiro Doki, Kiyokazu Nakajima, Takuya Yamada, M Hirota, Yasuaki Miyazaki, Tsutomu Nishida, Masahiko Tsujii
    Abstract:

    Background and study aims: Steady Pressure automatically controlled endoscopy (SPACE) is a new insufflation system that provides constant carbon dioxide (CO2) insufflation Pressure during prolonged procedures. The system consists of an overtube, a surgical insufflator, and a newly developed leak-proof valve. The aims of this study were to validate the feasibility and safety of SPACE for esophageal endoscopic submucosal dissection (ESD). Patients and methods: This was a clinical phase I trial, involving 10 patients who underwent esophageal ESD. The primary end point was the rate of adverse events within 30 days (grade 0 to 4). Secondary end points were changes in partial Pressure of carbon dioxide (PaCO2) and vital signs during ESD, completion rate of ESD, and degree of abdominal distension by patient assessment and radiographic grading. Results: All adverse events were Grade 2 or less. Mild PaCO2 elevation after ESD was noted; however, no associated symptoms were reported. The procedure was completed under SPACE alone in 8 of 10 patients. Minimal post-procedural bowel distension was observed. Conclusions: In this small pilot study, SPACE was feasible and appeared to be safe. Further study with larger case numbers is required to demonstrate efficacy and safety. Clinical trial registration: UMIN000005434

Kiyokazu Nakajima - One of the best experts on this subject based on the ideXlab platform.

  • percutaneous endoscopic gastrostomy under Steady Pressure automatically controlled endoscopy first clinical series
    World Journal of Gastrointestinal Endoscopy, 2016
    Co-Authors: Hiroyuki Imaeda, Kiyokazu Nakajima, Naoki Hosoe, Masanori Nakahara, Shinichiro Zushi, Motohiko Kato, Kazuhiro Kashiwagi, Yasushi Matsumoto, Kayoko Kimura, Rieko Nakamura
    Abstract:

    Percutaneous endoscopic gastrostomy under Steady Pressure automatically controlled endoscopy: First clinical series

  • Dynamic article: Steady Pressure CO2 colonoscopy; its feasibility and underlying mechanism.
    Diseases of The Colon & Rectum, 2014
    Co-Authors: Masashi Hirota, Yasuhiro Miyazaki, Tsuyoshi Takahashi, Makoto Yamasaki, Shuji Takiguchi, Masaki Mori, Yuichiro Doki, Kiyokazu Nakajima
    Abstract:

    Steady Pressure automatically controlled endoscopy is a new insufflation concept, achieving a laparoscopy-like Steady environment in the upper GI tract, recently reported in the esophagus. The purpose of this work was to validate the feasibility and safety of Steady Pressure automatically controlled endoscopy in the lower GI tract and to identify major factors that enable it. This was a nonsurvival animal study using canine models. The study was conducted in an academic center. Canine models were used in this study. In experiment 1, Steady Pressure automatically controlled endoscopy was attempted in the cecum with insufflation Pressures of 4, 8, and 12 mm Hg. We assessed performance by video review and continuous intracecal Pressure monitoring. Next, Steady Pressure automatically controlled endoscopy was performed for 20 minutes under optimal Pressure, 8 mm Hg (n = 10). In experiment 2, Steady Pressure automatically controlled endoscopy was attempted in the rectum with or without artificial colonic flexure and with either low (8 mm Hg) or high (16 mm Hg) insufflation Pressure to assess the effects of anatomic flexure and insufflation Pressure on the establishment of Steady Pressure automatically controlled endoscopy (n = 6). We measured multipoint intraluminal Pressure monitoring in the upstream bowel, as well as cardiopulmonary parameters. For experiment 1, Steady Pressure automatically controlled endoscopy in cecum was successful at all of the tested insufflation Pressures; 8 mm Hg provided the optimal result. Steady Pressure automatically controlled endoscopy was safely performed for 20 minutes at 8 mm Hg without any cardiopulmonary parameter changes or intraluminal Pressure elevation in the upstream bowel. For experiment 2, confinement of the Steady Pressure environment to the rectum was achieved only with the assistance of colonic flexure and at 8 mm Hg insufflation Pressure. In other conditions, the insufflated gas extended throughout the entire colon. This study was limited by being an animal study. Steady Pressure automatically controlled endoscopy is feasible and safe in the lower GI tract under the optimized insufflation Pressure and in the presence of anatomical flexure (see Video, Supplemental Digital Content 1, http://links.lww.com/DCR/A150).

  • esophageal submucosal dissection under Steady Pressure automatically controlled endoscopy space a clinical feasibility study
    Endoscopy, 2014
    Co-Authors: Motohiko Kato, Makoto Yamasaki, Masaki Mori, Yuichiro Doki, Kiyokazu Nakajima, Takuya Yamada, M Hirota, Yasuaki Miyazaki, Tsutomu Nishida, Masahiko Tsujii
    Abstract:

    Background and study aims: Steady Pressure automatically controlled endoscopy (SPACE) is a new insufflation system that provides constant carbon dioxide (CO2) insufflation Pressure during prolonged procedures. The system consists of an overtube, a surgical insufflator, and a newly developed leak-proof valve. The aims of this study were to validate the feasibility and safety of SPACE for esophageal endoscopic submucosal dissection (ESD). Patients and methods: This was a clinical phase I trial, involving 10 patients who underwent esophageal ESD. The primary end point was the rate of adverse events within 30 days (grade 0 to 4). Secondary end points were changes in partial Pressure of carbon dioxide (PaCO2) and vital signs during ESD, completion rate of ESD, and degree of abdominal distension by patient assessment and radiographic grading. Results: All adverse events were Grade 2 or less. Mild PaCO2 elevation after ESD was noted; however, no associated symptoms were reported. The procedure was completed under SPACE alone in 8 of 10 patients. Minimal post-procedural bowel distension was observed. Conclusions: In this small pilot study, SPACE was feasible and appeared to be safe. Further study with larger case numbers is required to demonstrate efficacy and safety. Clinical trial registration: UMIN000005434

  • esophageal submucosal dissection under Steady Pressure automatically controlled endoscopy space a randomized preclinical trial
    Endoscopy, 2012
    Co-Authors: Kiyokazu Nakajima, Makoto Yamasaki, Motohiko Kato, Shusaku Tsutsui, Kazuhiro Yasuda, Kazuki Sumiyama, Yasuaki Miyazaki, Jeongho Moon, Tomomi Yamada, Naohisa Yahagi
    Abstract:

    Background and study aims: A new overtube system has been developed for Steady Pressure automatically controlled endoscopy (SPACE) in the gastrointestinal tract. The objectives of this study were to validate the feasibility and safety of SPACE in the esophagus, and to evaluate its potential advantages over conventional (manually insufflating) endoscopy in endoscopic submucosal dissection (ESD). Methods: This was a multicenter preclinical trial using acute porcine models (n = 20). In Experiment 1 (feasibility/safety study), SPACE was attempted in the esophagus with continuous monitoring of cardiopulmonary parameters and intraluminal Pressures in the downstream bowel. Different insufflation Pressures were tested to optimize the insufflation condition. Each session was video-recorded and scored by blinded reviewers. In Experiment 2 (randomized trial), esophageal ESD was attempted using either SPACE or conventional endoscopy, and results were compared. Results: In Experiment 1, SPACE was performed safely without intraluminal Pressure elevation in the downstream bowel. According to video review, SPACE provided more stable, reproducible, and rapid visualization than conventional endoscopy. The insufflation Pressure was optimized at 14 mmHg for esophageal SPACE. In Experiment 2, ESD was completed in all animals. The ESD time was significantly shorter with SPACE compared with conventional endoscopy (1326 vs. 1616 seconds; P  = 0.009). Responses to questionnaires showed that 94 % – 100 % of participants considered SPACE to provide improved exposure and more uniform tissue tension than conventional endoscopy. Other data were comparable. Conclusions: SPACE is feasible, safe, and potentially effective for complicated endoscopic procedures, such as ESD. SPACE improves and standardizes endoscopic exposure and tissue tension. A clinical study is required to further confirm its safety and clinical effectiveness.

Masahiko Tsujii - One of the best experts on this subject based on the ideXlab platform.

  • gastric endoscopic submucosal dissection under Steady Pressure automatically controlled endoscopy space a multicenter randomized preclinical trial
    Surgical Endoscopy and Other Interventional Techniques, 2015
    Co-Authors: Takuya Yamada, Tsuyoshi Takahashi, Motohiko Kato, M Hirota, Shusaku Tsutsui, Kazuhiro Yasuda, Kazuki Sumiyama, Masahiko Tsujii, Tetsuo Takehara, Masaki Mori
    Abstract:

    Background Steady Pressure automatically controlled endoscopy (SPACE) is a new modality that eliminates on-demand insufflation but enables automatic insufflation in the gastrointestinal tract. Though its use in porcine esophageal ESD was reported to be promising, its applicability and potential effectiveness to gastric procedures have not been evaluated.

  • esophageal submucosal dissection under Steady Pressure automatically controlled endoscopy space a clinical feasibility study
    Endoscopy, 2014
    Co-Authors: Motohiko Kato, Makoto Yamasaki, Masaki Mori, Yuichiro Doki, Kiyokazu Nakajima, Takuya Yamada, M Hirota, Yasuaki Miyazaki, Tsutomu Nishida, Masahiko Tsujii
    Abstract:

    Background and study aims: Steady Pressure automatically controlled endoscopy (SPACE) is a new insufflation system that provides constant carbon dioxide (CO2) insufflation Pressure during prolonged procedures. The system consists of an overtube, a surgical insufflator, and a newly developed leak-proof valve. The aims of this study were to validate the feasibility and safety of SPACE for esophageal endoscopic submucosal dissection (ESD). Patients and methods: This was a clinical phase I trial, involving 10 patients who underwent esophageal ESD. The primary end point was the rate of adverse events within 30 days (grade 0 to 4). Secondary end points were changes in partial Pressure of carbon dioxide (PaCO2) and vital signs during ESD, completion rate of ESD, and degree of abdominal distension by patient assessment and radiographic grading. Results: All adverse events were Grade 2 or less. Mild PaCO2 elevation after ESD was noted; however, no associated symptoms were reported. The procedure was completed under SPACE alone in 8 of 10 patients. Minimal post-procedural bowel distension was observed. Conclusions: In this small pilot study, SPACE was feasible and appeared to be safe. Further study with larger case numbers is required to demonstrate efficacy and safety. Clinical trial registration: UMIN000005434

Takuya Yamada - One of the best experts on this subject based on the ideXlab platform.

  • gastric endoscopic submucosal dissection under Steady Pressure automatically controlled endoscopy space a multicenter randomized preclinical trial
    Surgical Endoscopy and Other Interventional Techniques, 2015
    Co-Authors: Takuya Yamada, Tsuyoshi Takahashi, Motohiko Kato, M Hirota, Shusaku Tsutsui, Kazuhiro Yasuda, Kazuki Sumiyama, Masahiko Tsujii, Tetsuo Takehara, Masaki Mori
    Abstract:

    Background Steady Pressure automatically controlled endoscopy (SPACE) is a new modality that eliminates on-demand insufflation but enables automatic insufflation in the gastrointestinal tract. Though its use in porcine esophageal ESD was reported to be promising, its applicability and potential effectiveness to gastric procedures have not been evaluated.

  • esophageal submucosal dissection under Steady Pressure automatically controlled endoscopy space a clinical feasibility study
    Endoscopy, 2014
    Co-Authors: Motohiko Kato, Makoto Yamasaki, Masaki Mori, Yuichiro Doki, Kiyokazu Nakajima, Takuya Yamada, M Hirota, Yasuaki Miyazaki, Tsutomu Nishida, Masahiko Tsujii
    Abstract:

    Background and study aims: Steady Pressure automatically controlled endoscopy (SPACE) is a new insufflation system that provides constant carbon dioxide (CO2) insufflation Pressure during prolonged procedures. The system consists of an overtube, a surgical insufflator, and a newly developed leak-proof valve. The aims of this study were to validate the feasibility and safety of SPACE for esophageal endoscopic submucosal dissection (ESD). Patients and methods: This was a clinical phase I trial, involving 10 patients who underwent esophageal ESD. The primary end point was the rate of adverse events within 30 days (grade 0 to 4). Secondary end points were changes in partial Pressure of carbon dioxide (PaCO2) and vital signs during ESD, completion rate of ESD, and degree of abdominal distension by patient assessment and radiographic grading. Results: All adverse events were Grade 2 or less. Mild PaCO2 elevation after ESD was noted; however, no associated symptoms were reported. The procedure was completed under SPACE alone in 8 of 10 patients. Minimal post-procedural bowel distension was observed. Conclusions: In this small pilot study, SPACE was feasible and appeared to be safe. Further study with larger case numbers is required to demonstrate efficacy and safety. Clinical trial registration: UMIN000005434